Viking Therapeutics, Inc. ranks third on the list of 11 Best Future Stocks to Buy Now. The company is developing treatments for metabolic disorders like obesity and NASH, with its lead candidate, VK2735, showing promising Phase 3 trial results for obesity and obesity with type 2 diabetes.

Viking Therapeutics, Inc. (VKTX) has completed enrollment in a Phase 2 trial for an oral version of VK2735, with top-line results expected later in 2025. The company is also expanding its pipeline with a novel amylin agonist program and advancing other programs targeting lipid metabolism.

With $808 million in cash and a robust pipeline, Viking Therapeutics, Inc. (NASDAQ:VKTX) is well-positioned for upcoming milestones. The Phase 3 VK2735 trials and pending oral trial results are crucial near-term catalysts for the company’s growth and success.

Read more at Yahoo Finance: Viking Therapeutics, Inc. (VKTX) Nears Obesity Drug Breakthrough with Phase 3 VK2735 Trial